Apollon Wealth Management’s PTC Therapeutics PTCT Stock Holding History

Apollon Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$538K	Sell	6,595 -744	-10%	-$53.7K	0.01%	978
2026 Q1	$500K	Sell	7,339 -27	-0.4%	-$1.91K	0.01%	858
2025 Q4	$560K	Sell	7,366 -1,473	-17%	-$107K	0.01%	793
2025 Q3	$542K	Hold	8,839	–	–	0.01%	796
2025 Q2	$432K	Hold	8,839	–	–	0.01%	852
2025 Q1	$450K	Hold	8,839	–	–	0.01%	793
2024 Q4	$399K	Sell	8,839 -8,839	-50%	-$378K	0.01%	834
2024 Q3	$656K	Hold	17,678	–	–	0.02%	623
2024 Q2	$541K	Hold	17,678	–	–	0.02%	647
2024 Q1	$514K	Sell	17,678 -4	-0%	-$112	0.02%	689
2023 Q4	$487K	Buy	17,682 +4	+0%	+$91	0.02%	663
2023 Q3	$396K	Hold	17,678	–	–	0.02%	608
2023 Q2	$719K	Buy	+17,678	New	+$865K	0.03%	497

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Apollon Wealth Management's PTCT Position: Q2 2026 in Review

Apollon Wealth Management reduced its PTC Therapeutics (PTCT) stake by 10% in Q2 2026, selling an estimated $53.7K and leaving 6,595 shares worth $538K. The position accounts for 0.01% of the portfolio, ranked #978.

Apollon Wealth Management first reported a position in PTCT in Q2 2023 and has held it in 13 quarters since. The position peaked at $719K in Q2 2023. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Apollon Wealth Management held 6,595 shares of PTC Therapeutics worth $538K as of Q2 2026.
Apollon Wealth Management sold 744 PTC Therapeutics shares in Q2 2026, an estimated $53.7K.
PTC Therapeutics made up 0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #978 holding.
Apollon Wealth Management first reported a position in PTC Therapeutics in Q2 2023 and has held it in 13 quarters since.
Apollon Wealth Management's PTC Therapeutics position peaked at $719K in Q2 2023.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.